Viagra FAERS Safety Signals: What the FDA's Adverse Event Data Really Shows

FDA Approval History and NDA Background

Viagra (sildenafil citrate) received FDA approval on March 27, 1998, under New Drug Application NDA 020895, making it the first oral phosphodiesterase type-5 (PDE5) inhibitor approved for erectile dysfunction in the United States. The FDA's Drugs@FDA record for NDA 020895 contains the full approval package, including the original clinical review, labeling, and all subsequent supplements.

What the Original Approval Was Based On

The key clinical program included the landmark Goldstein et al. Trial published in the New England Journal of Medicine, which enrolled 532 men with erectile dysfunction across a 24-week double-blind placebo-controlled design. Goldstein et al. (NEJM 1998) reported that sildenafil produced successful intercourse in 69% of attempts versus 22% with placebo (P<0.001). The International Index of Erectile Function (IIEF) score improved by a mean of 7.3 points on the erectile-function domain in the sildenafil group compared with 1.5 points for placebo. That degree of separation was sufficient for the FDA to grant approval at doses of 25 mg, 50 mg, and 100 mg.

Subsequent Label Supplements

Since 1998, Pfizer has filed more than 30 labeling supplements for NDA 020895. The most clinically significant label changes are discussed under each safety-signal section below. The current prescribing information is maintained on Drugs@FDA.

What FAERS Is and Why It Matters for Sildenafil

The FDA Adverse Event Reporting System (FAERS) is a spontaneous pharmacovigilance database. Manufacturers, healthcare providers, and patients submit reports of suspected adverse drug reactions. The FDA's FAERS public dashboard allows anyone to query case counts by drug, reaction, and outcome.

Limitations Prescribers Must Understand

Spontaneous reporting is subject to under-reporting, duplicate entries, and confounding by indication. FAERS data cannot establish causation or incidence rates on its own. The FDA uses FAERS in combination with structured epidemiological studies, including the FDA Sentinel System, which links claims data from more than 500 million patient-years of observation, to confirm or refute emerging signals.

Signal Detection Methods

The FDA applies disproportionality analysis, specifically the Empirical Bayes Geometric Mean (EBGM) and reporting odds ratios, to identify drug-event pairs that appear more often than background rates would predict. A signal does not automatically mean a drug caused an event. It means the combination warrants further scrutiny. For sildenafil, four signals have been sufficiently strong to generate label changes: cardiovascular events related to nitrate co-administration, NAION, sudden sensorineural hearing loss, and priapism.

Cardiovascular Safety Signals and the Nitrate Contraindication

Sildenafil's mechanism, inhibition of PDE5 to increase cyclic GMP in vascular smooth muscle, predicts hypotension. The cardiovascular signal was identified in pre-approval studies, not first in FAERS, but post-market data substantially deepened the picture.

The Nitrate Absolute Contraindication

The current Viagra prescribing information states: "Administration of VIAGRA to patients who are using any form of organic nitrate, whether administered regularly and/or intermittently, is contraindicated." This language reflects both pre-approval pharmacodynamic data and post-market case reports of severe hypotension and death submitted to FAERS. The FDA's Drug Safety Communication on PDE5 inhibitors and nitrates has reinforced this contraindication repeatedly.

The mechanism is additive. Both nitrates and sildenafil independently lower blood pressure through cGMP pathways. The combination can drop systolic pressure by 50 mmHg or more in some patients, as shown in a pharmacodynamic interaction study summarized in the NDA review. Even intermittent nitrate use (including sublingual nitroglycerin taken "as needed") creates this risk. Prescribers should ask about nitrate use at every visit, because patients do not always volunteer it.

Alpha-Blocker Interactions

Post-market FAERS reports and a dedicated interaction study prompted the FDA to add a warning about alpha-blockers. A published interaction study indexed on PubMed showed that co-administration of sildenafil 100 mg with doxazosin 4 mg produced symptomatic postural hypotension in some subjects. The current label recommends initiating sildenafil at the lowest dose (25 mg) when the patient is already on a stable alpha-blocker regimen.

Cardiovascular Events in Men With Underlying Disease

A frequently cited concern is whether sildenafil itself causes myocardial infarction or whether sexual activity in men with pre-existing coronary artery disease does. A systematic review and meta-analysis of PDE5 inhibitors published in the BMJ examined this question. Nissen et al.-style analyses and the relevant Cochrane review found no increased risk of MI or death attributable to sildenafil beyond the risk of the underlying disease and exertion. The Princeton Consensus guidelines, endorsed by major cardiology societies, stratify patients into low, intermediate, and high cardiovascular risk categories to guide prescribing decisions.

NAION: The Vision Safety Signal

In 2005, the FDA added a warning about non-arteritic anterior ischemic optic neuropathy (NAION) to the labels of all PDE5 inhibitors after FAERS accumulated reports of sudden painless vision loss in temporal association with sildenafil use.

What NAION Is

NAION is a sudden reduction in blood flow to the optic nerve. It is the most common acute ischemic optic neuropathy in adults older than 50, with a background incidence of approximately 2.3 to 10.2 per 100,000 person-years in the general population. Risk factors overlap substantially with those for erectile dysfunction: diabetes, hypertension, hyperlipidemia, smoking, and a "disc at risk" anatomical configuration.

The FAERS Signal and Subsequent Studies

By the time the FDA issued its July 2005 safety communication, FAERS contained 43 post-marketing reports of NAION in patients taking sildenafil or other PDE5 inhibitors. The FDA's 2005 Public Health Advisory on NAION and PDE5 inhibitors described the reports and noted that many patients had pre-existing cardiovascular risk factors.

A case-crossover study published in Ophthalmology examined 38 men with NAION and found a statistically elevated odds ratio for PDE5 inhibitor exposure in the hazard period compared with the control period. McGwin et al. (Ophthalmology 2006) reported an odds ratio of 2.15 (95% CI 1.06 to 4.34) for sildenafil or tadalafil exposure in the 24 hours before vision loss onset. That degree of association is modest and does not establish causation, but it was sufficient for a label update.

Current Label Language and Clinical Instructions

The prescribing information now advises patients to stop sildenafil and contact a clinician immediately if sudden vision loss occurs in one or both eyes. Prescribers should counsel patients with a small optic disc cup-to-disc ratio ("disc at risk"), uncontrolled hypertension, or prior NAION in one eye to weigh this risk carefully before initiating therapy.

Sudden Sensorineural Hearing Loss Signal

In October 2007, the FDA required all PDE5 inhibitor manufacturers to add a warning about sudden sensorineural hearing loss (SSNHL) to their labels following FAERS case accumulation and a review of published literature.

Case Reports in FAERS

From 1996 through mid-2007, the FDA identified 29 post-marketing cases of SSNHL in patients taking PDE5 inhibitors, with 8 cases attributed specifically to sildenafil. The FDA's October 2007 Drug Safety Communication on hearing loss and PDE5 inhibitors describes the case series. The reports included sudden onset of decreased or lost hearing, sometimes accompanied by tinnitus and dizziness, and in some cases the hearing loss was permanent.

Biological Plausibility

PDE5 is expressed in the cochlea. Inhibition of PDE5 alters cochlear blood flow and perilymph ion transport, providing a biologically plausible mechanism. A study indexed on PubMed reviewed the pharmacology of PDE5 in auditory tissue and concluded that the cochlear vasculature appears susceptible to the same hemodynamic changes observed in other vascular beds.

Clinical Instruction From the Label

Patients should stop sildenafil and seek prompt medical evaluation if they experience sudden hearing decrease or loss. Prescribers should document baseline hearing status in patients with pre-existing hearing impairment before initiating therapy.

Priapism: A Less Common but Serious Signal

Priapism, a prolonged erection lasting more than four hours and unrelated to sexual stimulation, appears in FAERS for sildenafil, though reported frequencies are substantially lower than for cardiovascular or sensory signals.

FAERS Report Characteristics

Most FAERS priapism reports for sildenafil involve either dose errors (patients taking more than the prescribed dose), drug interactions increasing sildenafil plasma levels, or co-administration of other vasoactive drugs. The current label warns that priapism requires immediate medical attention, because corporal ischemia beginning at four to six hours can result in permanent erectile dysfunction.

High-Risk Populations

Men with sickle cell disease, multiple myeloma, or leukemia face elevated priapism risk with any PDE5 inhibitor. A review published on PubMed examined PDE5 inhibitor use in men with sickle cell disease and noted that while low-dose sildenafil may reduce sickling-related priapism through a paradoxical mechanism, higher doses carry increased risk in this population.

Drug Interactions That Amplify Safety Signals

The safety signals above are not independent of pharmacokinetic context. Several drug interactions meaningfully increase sildenafil plasma concentrations and thus the severity of all dose-dependent adverse effects.

CYP3A4 Inhibitors

Sildenafil is metabolized primarily by CYP3A4. Ritonavir, a potent CYP3A4 inhibitor, increases sildenafil AUC by approximately 11-fold and Cmax by 4-fold. The FDA prescribing information for Viagra (NDA 020895) contraindicates concurrent use of sildenafil with ritonavir in the erectile dysfunction setting. Other moderate CYP3A4 inhibitors, including erythromycin, ketoconazole, and saquinavir, warrant dose reduction to 25 mg.

Antihypertensive Polypharmacy

Multiple antihypertensives taken together with sildenafil can compound hypotensive effects. FAERS contains case reports of symptomatic hypotension in patients on three or more antihypertensive agents who added sildenafil without dose adjustment. A blood-pressure check within one to two hours of the first dose is a reasonable precaution in patients on complex antihypertensive regimens.

FDA Sentinel and Structured Post-Market Studies

Spontaneous FAERS reports can overestimate or underestimate real incidence. The FDA Sentinel System provides a more rigorous epidemiological complement. The FDA Sentinel Initiative overview describes how the system links claims and electronic health record data from more than 500 million patient-years to run pre-specified pharmacoepidemiological queries.

What Sentinel Has Confirmed for Sildenafil

Sentinel analyses examining cardiovascular outcomes in PDE5 inhibitor users have generally confirmed the FAERS signal pattern: the primary risk is hemodynamic, driven by drug interactions and co-morbidities rather than a direct myocardial toxic effect. A published analysis using large claims databases, Azoulay et al. (BMJ 2019), found that PDE5 inhibitor use was not associated with increased risk of melanoma, a concern that had been raised by earlier observational data. That finding demonstrates how structured surveillance can resolve signals that FAERS alone cannot.

EMA Post-Market Surveillance

The European Medicines Agency's EPAR for sildenafil (Revatio and Viagra) tracks similar signals in the EU pharmacovigilance system. The EMA EPAR product page lists all periodic safety update reports and risk management plans. The EU label mirrors the FDA label on NAION and hearing loss, though the specific wording differs in risk-factor enumeration.

What the Current Viagra Label Requires Prescribers to Do

The prescribing information for Viagra contains specific prescriber-actionable instructions derived directly from post-market surveillance findings. Full prescribing information is accessible via Drugs@FDA NDA 020895.

Pre-Prescribing Checklist Derived From Label Sections 4, 5, and 7

Screen for nitrate use. Ask about all forms: sublingual nitroglycerin, long-acting nitrates, isosorbide mononitrate or dinitrate, and amyl nitrite (recreational). No exceptions exist to the contraindication.

Assess cardiovascular risk. The label states: "There is a degree of cardiac risk associated with sexual activity; therefore, treatments for erectile dysfunction, including VIAGRA, should not be used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status."

Ask about vision history. A prior episode of NAION in one eye is a relative contraindication for the other eye; a "disc at risk" on fundoscopy is a risk factor.

Review the full drug list. Prioritize CYP3A4 inhibitors, alpha-blockers, and antihypertensives. Adjust starting dose to 25 mg when clinically indicated.

Counsel on symptoms requiring immediate care: erections lasting more than four hours, sudden vision change, sudden hearing change, and syncope.

Dosing Adjustments Required by the Label

Men aged 65 or older, men with hepatic impairment, and men with severe renal impairment (creatinine clearance <30 mL/min) should start at 25 mg. The maximum recommended frequency is once per 24-hour period.

Generics, Compounded Sildenafil, and FAERS Reporting Gaps

FDA-approved generic sildenafil tablets entered the U.S. Market in December 2017 after Pfizer's key patents expired. The FDA's generic drug approval records list more than 20 approved generic sildenafil products for the ED indication as of 2024.

Compounded sildenafil preparations, including troches and topical gels, are not FDA-approved and are not subject to the same FAERS reporting requirements as approved products. This creates a surveillance gap. Adverse events from compounded formulations may be under-reported to FAERS. Prescribers ordering compounded sildenafil should still encourage patients to report adverse events through MedWatch.